ENGN
enGene Holdings Inc.
1W: +0.7%
1M: -32.1%
3M: -7.6%
YTD: -18.5%
1Y: +33.5%
$7.21
-0.01 (-0.07%)
After Hours: $7.75 (+0.54, +7.49%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$25.0M
Congress—
ETF Holdings—
Key Statistics
Market Cap$369.1M
52W Range2.65-12.25
Volume186,796
Avg Volume448,322
Beta-0.28
Dividend—
Analyst Ratings
Company Info
CEORonald H. W. Cooper
Employees56
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-01
Websiteengene.com
7171 Rue Frederick Banting
Saint-Laurent H4S 1Z9
CA
Saint-Laurent H4S 1Z9
CA
514 332 4888
About enGene Holdings Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Latest News
HC Wainwright Brokers Increase Earnings Estimates for enGene
FY2030 Earnings Forecast for enGene Issued By HC Wainwright
enGene Holdings GAAP EPS of $0.44
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Moderate Buy” by Brokerages
enGene to Participate in Upcoming Investor Conferences
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Connolly Joan | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Boyd Matthew Ross | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Buck Jill | A-Award | 195,000 | $9.53 | 2026-01-30 |
| CHEUNG ANTHONY TZEYE | A-Award | 195,000 | $9.53 | 2026-01-30 |
| Giguere Lee | A-Award | 195,000 | $9.53 | 2026-01-30 |